190 related articles for article (PubMed ID: 29097142)
1. Exploring the feasibility of the use of biopolymers as a carrier in the formulation of amorphous solid dispersions - Part I: Gelatin.
Pas T; Vergauwen B; Van den Mooter G
Int J Pharm; 2018 Jan; 535(1-2):47-58. PubMed ID: 29097142
[TBL] [Abstract][Full Text] [Related]
2. Drug-carrier binding and enzymatic carrier digestion in amorphous solid dispersions containing proteins as carrier.
Pas T; Bergonzi A; Lescrinier E; Vergauwen B; Van den Mooter G
Int J Pharm; 2019 May; 563():358-372. PubMed ID: 30935916
[TBL] [Abstract][Full Text] [Related]
3. Ability of gelatin and BSA to stabilize the supersaturated state of poorly soluble drugs.
Pas T; Struyf A; Vergauwen B; Van den Mooter G
Eur J Pharm Biopharm; 2018 Oct; 131():211-223. PubMed ID: 30121247
[TBL] [Abstract][Full Text] [Related]
4. Preparation of Amorphous Solid Dispersions by Cryomilling: Chemical and Physical Concerns Related to Active Pharmaceutical Ingredients and Carriers.
Pas T; Bergonzi A; Michiels E; Rousseau F; Schymkowitz J; Koekoekx R; Clasen C; Vergauwen B; Van den Mooter G
Mol Pharm; 2020 Mar; 17(3):1001-1013. PubMed ID: 31961692
[TBL] [Abstract][Full Text] [Related]
5. The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers.
Van Duong T; Van den Mooter G
Expert Opin Drug Deliv; 2016 Dec; 13(12):1681-1694. PubMed ID: 27267583
[TBL] [Abstract][Full Text] [Related]
6. Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs.
Baghel S; Cathcart H; O'Reilly NJ
J Pharm Sci; 2016 Sep; 105(9):2527-2544. PubMed ID: 26886314
[TBL] [Abstract][Full Text] [Related]
7. A Novel Approach for Analyzing the Dissolution Mechanism of Solid Dispersions.
Ji Y; Paus R; Prudic A; Lübbert C; Sadowski G
Pharm Res; 2015 Aug; 32(8):2559-78. PubMed ID: 25715696
[TBL] [Abstract][Full Text] [Related]
8. The role of the carrier in the formulation of pharmaceutical solid dispersions. Part I: crystalline and semi-crystalline carriers.
Van Duong T; Van den Mooter G
Expert Opin Drug Deliv; 2016 Nov; 13(11):1583-1594. PubMed ID: 27321133
[TBL] [Abstract][Full Text] [Related]
9. Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers.
Sun DD; Lee PI
J Control Release; 2015 Aug; 211():85-93. PubMed ID: 26054795
[TBL] [Abstract][Full Text] [Related]
10. Development of novel darunavir amorphous solid dispersions with mesoporous carriers.
Zolotov SA; Demina NB; Zolotova AS; Shevlyagina NV; Buzanov GA; Retivov VM; Kozhukhova EI; Zakhoda OY; Dain IA; Filatov AR; Cheremisin AM
Eur J Pharm Sci; 2021 Apr; 159():105700. PubMed ID: 33429047
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs.
Van den Mooter G; Weuts I; De Ridder T; Blaton N
Int J Pharm; 2006 Jun; 316(1-2):1-6. PubMed ID: 16563676
[TBL] [Abstract][Full Text] [Related]
12. Freeze-dried amorphous dispersions for solubility enhancement of thermosensitive API having low molecular lipophilicity.
Kulthe VV; Chaudhari PD; Aboul-Enein HY
Drug Res (Stuttg); 2014 Sep; 64(9):493-8. PubMed ID: 24443307
[TBL] [Abstract][Full Text] [Related]
13. To enhance dissolution rate of poorly water-soluble drugs: glucosamine hydrochloride as a potential carrier in solid dispersion formulations.
Al-Hamidi H; Edwards AA; Mohammad MA; Nokhodchi A
Colloids Surf B Biointerfaces; 2010 Mar; 76(1):170-8. PubMed ID: 19945828
[TBL] [Abstract][Full Text] [Related]
14. Enhanced kinetic solubility profiles of indomethacin amorphous solid dispersions in poly(2-hydroxyethyl methacrylate) hydrogels.
Sun DD; Ju TC; Lee PI
Eur J Pharm Biopharm; 2012 May; 81(1):149-58. PubMed ID: 22233548
[TBL] [Abstract][Full Text] [Related]
15. Improved dissolution behavior of lipophilic drugs by solid dispersions: the production process as starting point for formulation considerations.
Srinarong P; de Waard H; Frijlink HW; Hinrichs WL
Expert Opin Drug Deliv; 2011 Sep; 8(9):1121-40. PubMed ID: 21722000
[TBL] [Abstract][Full Text] [Related]
16. Effect of drug-carrier interaction on the dissolution behavior of solid dispersion tablets.
Srinarong P; Kouwen S; Visser MR; Hinrichs WL; Frijlink HW
Pharm Dev Technol; 2010; 15(5):460-8. PubMed ID: 20735300
[TBL] [Abstract][Full Text] [Related]
17. Delivery of poorly soluble compounds by amorphous solid dispersions.
Lee TW; Boersen NA; Hui HW; Chow SF; Wan KY; Chow AH
Curr Pharm Des; 2014; 20(3):303-24. PubMed ID: 23651395
[TBL] [Abstract][Full Text] [Related]
18. Drug Solubilization by Means of a Surface-Modified Edible Biopolymer Enabled by Hot Melt Extrusion.
Ong HJ; Pinal R
J Pharm Sci; 2018 Jan; 107(1):402-411. PubMed ID: 29074381
[TBL] [Abstract][Full Text] [Related]
19. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
Ghebremeskel AN; Vemavarapu C; Lodaya M
Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
[TBL] [Abstract][Full Text] [Related]
20. Different BCS Class II Drug-Gelucire Solid Dispersions Prepared by Spray Congealing: Evaluation of Solid State Properties and In Vitro Performances.
Bertoni S; Albertini B; Passerini N
Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32545643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
